

[198] CONTINUOUS MONITORING DEVICE FOR HEART ARRHYTHMIA AND HYPERTENSION

Eldad Shemesh¹, ¹ Cardiacsense

ABSTRACT TEMPLATE for Company Presentations

The maximum number of words for this abstract is 300 words.

You may delete the section instructions, leaving only the bolded bullet title.

Questions for Biotech/Pharma; Medical Devices and Health IT/Digital Health categories are:

- **Investment Rational**
CardiacSense develops a medical watch based on PPG technology for heart arrhythmia detection and cuff-less and continuous Blood Pressure measurement. Combined market of heart arrhythmia detection and BP measurement is a multibillion \$ market, CardiacSense watch is going through clinical trials now towards gaining regulatory approvals that are expected by the end of 2018. CardiacSense partnered with a tier1 semiconductor manufacturer that will manufacture CardiacSense MCM and partnered with a tier1 AED manufacturer for Cardiac Arrest detection. Management team is very experienced and multidisciplinary team.
- **Business Strategy**
CardiacSense watch will be sold, in short term, to hospitals, elderly homes and monitoring centers (under prescription). In the long term, the CardiacSense watch will be sold OTC.
- **Core Technology**
CardiacSense core competence is in PPG (PhotoPlatismoGraphy). Our IP is in movement cancelation (which is the Achilles Heal of the PPG technology).
- **Product Profile/Pipeline**
Product pipeline is (with the commercial watch): Q1/2019 is 24/7/365 Atrial Fibrillation detection. At Q1/2019 we will have SpO2 (over the finger). At Q4/2019 we should have BP (cuff-less and continuous) and Cardiac Arrest detection. At 2020 and 2021 we will focus on respiratory rate and SpO2 over the wrist.
- **What's Next?**
Preclinical / Clinicals: After receiving FDA/CE by the end of 2018, we will conduct a wide A-Fib detection clinical trial with Cleveland Clinic (2019). Right after that, we will initiate a multisite clinical trial in several locations (USA, EU, APAC).
Organizational plans: right after A round investment, R&D team will almost double to aggressively reach product pipeline.
Financial plans: A round (10M\$) on June 2018.